Proposal of a Novel Serological Algorithm Combining FIB-4 and Serum M2BPGi for Advanced Fibrosis in Nonalcoholic Fatty Liver Disease
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background/Aims: Noninvasive methods have become increasingly critical in the diagnosis of fibrosis in chronic liver diseases. Herein, we compared the diagnostic performance of serum Mac2 binding protein glycosylation isomer (M2BPGi) and other serological panels for fibrosis in patients with nonalcoholic fatty liver disease (NAFLD) and proposed an improved two-step diagnostic algorithm for advanced fibrosis. Methods: We enrolled 231 patients diagnosed with NAFLD who underwent a liver biopsy. We subsequently evaluated the diagnostic performance of serological panels, including serum M2BPGi, a fibrosis index based on four factors (FIB-4), aspartate aminotransferase-to-platelet ratio index (APRI), and NAFLD fibrosis score (NFS), in predicting the stage of liver fibrosis. We then constructed a two-step algorithm to better differentiate advanced fibrosis. Results: The areas under the receiver operating characteristic curves of serum M2BPGi, FIB-4, APRI, and NFS for advanced fibrosis (≥F3) were 0.823, 0.858, 0.779, and 0.827, respectively. To reduce the performance of unnecessary liver biopsy, we propose a two-step algorithm using FIB-4 as an initial diagnostic tool and serum M2BPGi (≥0.6) as an additional diagnostic method for patients classified as intermediate (23%). Using the proposed algorithm, the sensitivity, specificity, accuracy, positive predictive value, and negative predictive value were 0.812, 0.814, 0.814, 0.600, and 0.927, respectively. Conclusions: Serum M2BPGi is a simple and effective test for advanced fibrosis in patients with NAFLD. Application of the two-step algorithm based on FIB-4 and M2BPGi proposed here can improve diagnostic performance and reduce unnecessary tests, making diagnosis easily accessible, especially in primary medical centers.
Abstract
Background/Aims: Noninvasive methods have become increasingly critical in the diagnosis of fibrosis in chronic liver diseases. Herein, we compared the diagnostic performance of serum Mac2 binding protein glycosylation isomer (M2BPGi) and other serological panels for fibrosis in patients with nonalcoholic fatty liver disease (NAFLD) and proposed an improved two-step diagnostic algorithm for advanced fibrosis. Methods: We enrolled 231 patients diagnosed with NAFLD who underwent a liver biopsy. We subsequently evaluated the diagnostic performance of serological panels, including serum M2BPGi, a fibrosis index based on four factors (FIB-4), aspartate aminotransferase-to-platelet ratio index (APRI), and NAFLD fibrosis score (NFS), in predicting the stage of liver fibrosis. We then constructed a two-step algorithm to better differentiate advanced fibrosis. Results: The areas under the receiver operating characteristic curves of serum M2BPGi, FIB-4, APRI, and NFS for advanced fibrosis (≥F3) were 0.823, 0.858, 0.779, and 0.827, respectively. To reduce the performance of unnecessary liver biopsy, we propose a two-step algorithm using FIB-4 as an initial diagnostic tool and serum M2BPGi (≥0.6) as an additional diagnostic method for patients classified as intermediate (23%). Using the proposed algorithm, the sensitivity, specificity, accuracy, positive predictive value, and negative predictive value were 0.812, 0.814, 0.814, 0.600, and 0.927, respectively. Conclusions: Serum M2BPGi is a simple and effective test for advanced fibrosis in patients with NAFLD. Application of the two-step algorithm based on FIB-4 and M2BPGi proposed here can improve diagnostic performance and reduce unnecessary tests, making diagnosis easily accessible, especially in primary medical centers.
참고문헌 (44)
- Younossi ZM, "Global epidemiology of nonalcoholic fatty liver disease : meta-analytic assessment of prevalence, incidence, and outcomes", Hepatology, 64, pp.73~84 (2016)
- Li J, "Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019 : a systematic review and meta-analysis", Lancet Gastroenterol Hepatol, 4, pp.389~398 (2019)
- Riazi K, "The prevalence and incidence of NAFLD worldwide : a systematic review and meta-analysis", Lancet Gastroenterol Hepatol, 7, pp.851~861 (2022)
- Le MH, "Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical Bayesian approach", Clin Mol Hepatol, 28, pp.841~850 (2022)
- Ng CH, "Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease : prevalence, outcomes and implications of a change in name", Clin Mol Hepatol, 28, pp.790~801 (2022)
- Ekstedt M, "Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up", Hepatology, 61, pp.1547~1554 (2015)
- Hagström H, "Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD", J Hepatol, 67, pp.1265~1273 (2017)
- Leow WQ, "Non-alcoholic fatty liver disease : the pathologist’s perspective", Clin Mol Hepatol, 29(Suppl), pp.S302~S318 (2023)
- Reinson T, "Noninvasive serum biomarkers for liver fibrosis in NAFLD : current and future", Clin Mol Hepatol, 29(Suppl), pp.S157~S170 (2023)
- Yu JH, "Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease : current and future", Clin Mol Hepatol, 29(Suppl), pp.S136~S149 (2023)
- Zou X, "Serum WFA+-M2BP levels for evaluation of early stages of liver fibrosis in patients with chronic hepatitis B virus infection", Liver Int, 37, pp.35~44 (2017)
- Liu CH, "Serum Mac-2 binding protein glycosylation isomer to predict the severity of hepatic fibrosis in patients with hepatitis C virus infection", Diagnostics(Basel), 12, pp.2650~ (2022)
- Abe M, "Association between Wisteria floribunda agglutinin-positive Mac-2 binding protein and the fibrosis stage of non-alcoholic fatty liver disease", J Gastroenterol, 50, pp.776~784 (2015)
- Kuno A, "A serum"sweet-doughnut"protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis", Sci Rep, 3, pp.1065~ (2013)
- Razak F, "Defining obesity cut points in a multiethnic population", Circulation, 115, pp.2111~2118 (2007)
- Sterling RK, "Development of a simple noninvasive index to predict significant fibrosis in patients with HIV", HCV coinfection, 2006, pp.43, 1317~1325
- Angulo P, "The NAFLD fibrosis score : a noninvasive system that identifies liver fibrosis in patients with NAFLD", Hepatology, 45, pp.846~854 (2007)
- Wai CT, "A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C", Hepatology, 38, pp.518~526 (2003)
- Kleiner DE, "Design and validation of a histological scoring system for nonalcoholic fatty liver disease", Hepatology, 41, pp.1313~1321 (2005)
- Bedossa P, "An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group", Hepatology, 24, pp.289~293 (1996)
- Kanwal F, "Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease", Gastroenterology, 161, pp.1657~1669 (2021)
- European Association for the Study of the Liver, "EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis : 2021 update", J Hepatol, 75, pp.659~689 (2021)
- Cusi K, "American Association of Clinical Endocrinology Clinical Practice Guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings : co-sponsored by the American Association for the Study of Liver Diseases(AASLD)", Endocr Pract, 28, pp.528~562 (2022)
- Srivastava A, "Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease", J Hepatol, 71, pp.371~378 (2019)
- Konyn P, "Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease", Clin Mol Hepatol, 29(Suppl), pp.S43~S57 (2023)
- Ng CH, "The effect of diabetes and prediabetes on the prevalence, complications and mortality in nonalcoholic fatty liver disease", Clin Mol Hepatol, 28, pp.565~574 (2022)
- Lee JH, "The usefulness of metabolic score for insulin resistance for the prediction of incident non-alcoholic fatty liver disease in Korean adults", Clin Mol Hepatol, 28, pp.814~826 (2022)
- Song W, "Association between sarcopenic obesity status and nonalcoholic fatty liver disease and fibrosis", Gut Liver, 17, pp.130~138 (2023)
- Dulai PS, "Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease : systematic review and meta-analysis", Hepatology, 65, pp.1557~1565 (2017)
- Rinella ME, "AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease", Hepatology, 77, pp.1797~1835 (2023)
- Vilar-Gomez E, "Non-invasive assessment of non-alcoholic fatty liver disease : clinical prediction rules and blood-based biomarkers", J Hepatol, 68, pp.305~315 (2018)
- McPherson S, "Are simple noninvasive scoring systems for fibrosis reliable in patients with NAFLD and normal ALT levels?", Eur J Gastroenterol Hepatol, 25, pp.652~658 (2013)
- Lee J, "Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events : a systematic review", Liver Int, 41, pp.261~270 (2021)
- Han S, "Accuracy of noninvasive scoring systems in assessing liver fibrosis in patients with nonalcoholic fatty liver disease : a systematic review and metaanalysis", Gut Liver, 16, pp.952~963 (2022)
- Sande JA, "Ultrasound shear wave elastography and liver fibrosis : a prospective multicenter study", World J Hepatol, 9, pp.38~47 (2017)
- Musso G, "Metaanalysis : natural history of non-alcoholic fatty liver disease(NAFLD)and diagnostic accuracy of non-invasive tests for liver disease severity", Ann Med, 43, pp.617~649 (2011)
- McPherson S, "Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis", Am J Gastroenterol, 112, pp.740~751 (2017)
- Goh GB, "Clinical spectrum of non-alcoholic fatty liver disease in diabetic and nondiabetic patients", BBA Clin, 3, pp.141~145 (2014)
- Bekki Y, "Hepatic stellate cells secreting WFA+-M2BP : its role in biological interactions with Kupffer cells", J Gastroenterol Hepatol, 32, pp.1387~1393 (2017)
- Nishikawa H, "Clinical significance of serum Wisteria floribunda agglutinin positive Mac-2-binding protein level in non-alcoholic steatohepatitis", Hepatol Res, 46, pp.1194~1202 (2016)
- Lai LL, "Serum Wisteria floribunda agglutininpositive Mac-2 binding protein in non-alcoholic fatty liver disease", PLoS One, 12, pp.e0174982~ (2017)
- Paik JM, "Global burden of NAFLD and chronic liver disease among adolescents and young adults", Hepatology, 75, pp.1204~1217 (2022)
- Anstee QM, "Noninvasive tests accurately identify advanced fibrosis due to NASH : baseline data from the STELLAR Trials", Hepatology, 70, pp.1521~1530 (2019)
- Srivastava A, "Cost-comparison analysis of FIB-4, ELF and Fibroscan in community pathways for non-alcoholic fatty liver disease", BMC Gastroenterol, 19, pp.122~ (2019)